The rAAV products carrying tumor-associated epitope genes currently used in ACTL treatment are as follows:
|
1.AAV/CEA (carcinoembryonic antigen)
|
2.AAV/Her-2/neu (Her-2/neu antigen)
|
|
3.AAV/CK19 (cytokeratin 19)
|
4.AAV/MAGE-A3 (a melanoma antigen)
|
|
5.AAV/PSMA (prostate specific membrane antigen)
|
6.AAV/BA46 (milk protein antigen)
|
|
7. AAV/Bcg1 (breast cancer related antigen-I)
|
8.AAV/AFP (alpha-fetoprotein)
|
|
9.AAV/HPV E6-E7 (human papillomavirus E6 and E7 antigens)
|
10.AAV/LMP-1 (EB virus LMP-1 antigen)
|
|
11.AAV/PSA (Prostate Specific Antigen)
|
12.AAV/PAP (Prostatic Acid Phosphatase Antigen)
|
|
13.AAV/HM1.24 (multiple myeloma antigen)
|
14.AAV/SPANX (a tumor-testicular antigen SPANX)
|
|
15.AAV/SP17 (sperm protein 17 antigen)
|
16. AAV/SCC (Squamous Cell Carcinoma Antigen)
|
|
17.AAV/Survivin (auxin antigen)
|
18. AAV/MUC-1 (Mucin Antigen)
|
|
19. AAV/G250 (carbonic anhydrase antigen)
|
20. AAV/CT10 (Tumor-testis antigen 10)
|
|
21. AAV/CD20 |
22. AAV/CD269 |
It is expected that within five years, dozens of rAAVs carrying tumor antigens or tumor-related antigens will be completed, bringing the total number of products to more than 50.
